Transmembrane protein expressed in prostate and other cancers
CA 2369413 C · Owner: Saffran, Douglas C. · Inventors: Raitano, Arthur B.; Leong, Kahan; Afar, Daniel E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 12, 2000 and granted July 9, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 12, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 12, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.